Clin2Atlas
AtlasInfectionsRespiratory infections and tuberculosis

Otitis media

4Curable or preventable in mostAI-generated
Burden-over-time charts — how many people this disease affects and whether that number is rising or falling — are coming to this page. The treatability read, milestones, and live trial pipeline below are current.

Milestones

dot size = significance
199020002010202020251989 — Cefixime approved (FDA)1991 — Clarithromycin approved (FDA)1991 — Azithromycin approved (FDA)1991 — Cefprozil anhydrous, (e)- approved (FDA)1992 — Cefpodoxime proxetil approved (FDA)1995 — Ceftibuten approved (FDA)1997 — Cefdinir approved (FDA)
1989: Drug approval — Cefixime approved (FDA). 1991: Drug approval — Clarithromycin approved (FDA). 1991: Drug approval — Azithromycin approved (FDA). 1991: Drug approval — Cefprozil anhydrous, (e)- approved (FDA). 1992: Drug approval — Cefpodoxime proxetil approved (FDA). 1995: Drug approval — Ceftibuten approved (FDA). 1997: Drug approval — Cefdinir approved (FDA)

What's being tested now

2019: 2 trials started2020: 1 trials started2021: 4 trials started2022: 3 trials started2023: 1 trials started2024: 1 trials started2025: 12 trials started2026: 11 trials started2020202612

Trials started per year, stacked by phase (darker = later phase). Source: ClinicalTrials.gov via Clin2, which tracks studies recruiting in recent years — early years undercount.

See all 30 active Otitis Media trials on Clin2 →

Related

Lower respiratory infectionsUpper respiratory infectionsCOVID-19

Burden estimates: IHME Global Burden of Disease Study. Drug indications: ChEMBL (CC BY-SA). Trial data: ClinicalTrials.gov via Clin2. Velocity, acceleration, and turning points are computed by Clin2 — how this page is made. Treatability describes what medicine can do, not what is available everywhere. This page describes populations, not people, and is not medical advice.